Myc and Mammary Cancer: Myc is a Downstream Effector of the ErbB2 Receptor Tyrosine Kinase (original) (raw)
REFERENCES
C. Escot, C. Theillet, R. Lidereau, F. Spyratos, M. H. Champeme, J. Gest, and R. Callahan (1986). Genetic alteration of the c-myc proto-oncogene (MYC) in human primary breast carcinomas. Proc. Natl. Acad. Sci. U.S.A. 83:4834–4838. Google Scholar
M.D. Cole and S.B. McMahon (1999). The Myc oncoprotein:A critical evaluation of transactivation and target gene regulation. Oncogene18:2916–2924. Google Scholar
C. V. Dang (1999). c-Myc target genes involved in cell growth, apoptosis and metabolism. Mol. Cell. Biol.19:1–11. Google Scholar
M. Henriksson and B. Lüscher (1996). Proteins of the Myc network: Essential regulators of cell growth and differentiation. Adv. Cancer Res.68:109–182. Google Scholar
B. Luscher and L.-G. Larsson (1999). The basic region/helixloop-helix/leucine zipper domain of Myc proto-oncoproteins: Function and regulation. Oncogene18:2955–2966. Google Scholar
C. Bouchard, P. Staller, and M. Eilers (1998). Control of cell proliferation by myc. Trends Cell Biol.8:202–206. Google Scholar
B. Amati, K. Alevizopoulos, and J. Vlach (1998). Myc and the cell cycle. Frontiers in Bioscience3:250–268. Google Scholar
G. C. Prendergast (1999). Mechanisms of apoptosis. Oncogene18:2967–2987. Google Scholar
M. K. Mateyak, A. J. Obaya, and J. M. Sedivy (1999). c-Myc regulates cyclin D-Cdk4 and-cdk6 activity but affects cell cycle progression at multiple independent points. Mol. Cell. Biol.19:4672–4683. Google Scholar
H. A. Lane, I. Beuvink, A. B. Motoyama, J. M. Daly, R. M. Neve, and N. E. Hynes (2000). ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol.20:3210–3223. Google Scholar
R. M. Neve, H. Sutterlüty, N. Pullen, H. A. Lane, J. M. Daly, W. Krek, and N. E. Hynes (2000). Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumor cells. Oncogene19:1647–1656. Google Scholar
M. Eilers, S. Schirm, and J. M. Bishop (1991). TheMYCprotein activates transcription of the α-prothymosin gene. EMBO J.10:133–141. Google Scholar
D. Dubik and R. P. C. Shiu (1992). Mechanism of estrogen activation of c-myc oncogene expression. Oncogene7:1587–1594. Google Scholar
R. Strange, F. Li, S. Saurer, A. Burkhardt, and R. R. Friis (1992). Apoptotic cell death and tissue remodeling during mousemammary gland involution. Development115:49–68. Google Scholar
L. D. Odom, J. M. Barrett, C. G. Pantazis, L. D. Stoddard, and P. G. McDonough (1989). Immunohistochemical study of ras and myc proto-oncogene polypeptide expression in the human menstrual cycle. Am. J. Obstet. Gynecol.161:1663–1668. Google Scholar
D. Askew, R. Ashmun, B. Simmons, and J. Cleveland (1991). Constitutive c-myc expression in IL-3-dependent myeloid cell lines suppresses cycle arrest and accelerates apoptosis. Oncogene6:1915–1922. Google Scholar
G. Evan and T. Littlewood (1998). A matter of life and cell death. Science281:1317–1322. Google Scholar
S. B. McMahon, H. A. VanBuskirk, K. A. Dugan, T. D. Copeland, and M.D. Cole (1998). The novelATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell94:363–374. Google Scholar
S. B. McMahon, M. A. Wood, and M. D. Cole (2000). The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol. Cell. Biol.20:556–562. Google Scholar
S. Han, K. Park, H.-Y. Kim, M.-S. Lee, H.-J. Kim, Y.-D. Kim, Y. J. Yuh, S. R. Kim, and H. S. Suh (2000). Clinical impliction of altered expression of Mad1 protein in human breast carcinoma. Cancer88:1623–1632. Google Scholar
I. Perez-Roger, S.-H. Kim, B. Griffiths, A. Sewing, and H. Land (1999). Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21Cip1. EMBO J.18:5310–5320. Google Scholar
C. Bouchard, K. Thieke, A. Maier, R. Saffrich, J. Hanley-Hyde, W. Ansorge, S. Reed, P. Sicinski, J. Bartek, and M. Eilers (1999). Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J.18:5321–5333. Google Scholar
C. E. Nesbit, J. M. Tersak, and E. V. Prochownik (1999). MYC oncogenes and human neoplastic disease. Oncogene18:3004–3016. Google Scholar
S. J. Nass and R. B. Dickson (1997). Defining a role for c-myc in breast tumorigenesis. Breast Cancer Res. Treat.44:1–22. Google Scholar
I. Bieche, I. Laurendeau, S. Tozlu, M. Olivi, D. Vidaud, R. Lidereau, and M. Vidaus (1999). Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcriptase-PCR assay. Cancer Res.59:2759–2765. Google Scholar
K. Bhatia, K. Huppi, G. Spangler, D. Siwarski, R. Iyer, and I. Magrath (1993). Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nature Genet.5:56–61. Google Scholar
S. E. Salghetti, S. Y. Kim, and W. P. Tansey (1999). Destruction of Myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize Myc. EMBO J.18:717–726. Google Scholar
M. J. West, M. Stoneley, and A. E. Willis (1998). Translational induction of the c-myc oncogene via activation of the FRAP/TOR signaling pathway. Oncogene17:769–780. Google Scholar
R. Sears, G. Lone, J. DeGregori, and J. R. Nevins (1999). Ras enhances Myc protein stability. Mol. Cell.3:169–179. Google Scholar
A. Scorilas, T. Trangas, J. Yotis, C. Pateras, and M. Talieri (1999). Determination of c-myc amplification and overexpression in breast cancer patients: Evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Brit. J. Cancer81:1385–1391. Google Scholar
M. Cuny, A. Kramar, F. Courjal, V. Johannsdottir, B. Iacopetta, H. Fontaine, J. Grenier, S. Culine, and C. Theillet (2000). Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res.60:1077–1083. Google Scholar
D. W. Felsher and J. M. Bishop (1999). Transient excess of MYC activity can elicit genomic instability. Proc. Natl. Acad. Sci. U.S.A.96:3940–3944. Google Scholar
S. Mai, J. Hanley-Hyde, and M. Fluri (1996). C-myc overexpression addociated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene12:277–288. Google Scholar
L. M. Sargent, N. D. Sanderson, and S. S. Thorgiersson (1996). Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinomas in transgenic mice harboring c-myc and transforming growth factor α. Cancer Res.56:2137–2142. Google Scholar
Q. Li and C. V. Dang (1999). c-Myc overexpression uncouples DNA replication from mitosis. Mol. Cell. Biol.19:5339–5351. Google Scholar
S. J. Nass and R. B. Dickson (1998). Epidermal growth factordependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc. Clin. Cancer Res.4:1813–1822. Google Scholar
J. Wang, L.Y. Xie, S. Allan, D. Beach, and G. H. Hannon (1998). Myc activates telomerase. Genes Dev.12:1769–1774. Google Scholar
M. H. Jamerson, M.D. Johnson, and R.B. Dickson (2000). Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene19:1065–1071. Google Scholar
T. A. Rose-Hellekant and E. P. Sandgren (2000). Transforming growth factor α-and _c-myc_-induced mammary carcinogenesis in transgenic mice. Oncogene19:1092–1096. Google Scholar
D. J. Reise, II and D. F. Stern (1998). Specificity within the EGF family/ErbB receptor family signaling network. BioEssays20:41–48. Google Scholar
D. S. Salomon, R. Brandt, F. Ciardiello and N. Normanno (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol.19:183–232. Google Scholar
C. K. Tang and M. E. Lippman (1998). EGF family receptors and their ligands in human cancer. In B. W. O'Malley (ed.), Hormones and Signaling, Vol. I., Academic Press, San Diego, California, pp. 113–165. Google Scholar
L. T. Amundadottir, S. J. Nass, G. J. Berchem, M. D. Johnson, and R. B. Dickson (1996). Cooperation of TGFα and c-Myc in mouse mammary tumorigenesis: Coordinated stimulation of growth and suppression of apoptosis. Oncogene13:757–765. Google Scholar
L. T. Amundadottir, M. D. Johnson, G. Merlino, G. H. Smith, and R. B. Dickson (1995). Synergistic interaction of transforming growth factor α and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth Differ.6:737–748. Google Scholar
E. P. Sandgren, N. C. Luetteke, R. D. Palmiter, R. L. Brinster, and D. C. Lee (1990). Overexpression of TGF α in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia and carcinoma of the breast. Cell61:1121–1135. Google Scholar
E. Sinn, W. Muller, P. Pattengale, I. Tepler, R. Wallace, and P. Leder (1987). Coexpression ofMMTV/v-Ha-ras andMMTV/cmyc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell49:465–475. Google Scholar
J. E. Hundley, S.K. Koester, D.A. Troyer, S.G. Hilsenbeck, and R. E. Barrington (1997). Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. Cancer Res.57:600–603. Google Scholar
R. P. Bissonnette, F. Echeverri, A. Mahboubi, and D. R. Green (1992). Apoptotic cell death induced by c-myc is inhibited by _bcl_-2. Nature359:552–554. Google Scholar
A. F. Fanidi, E. A. Harrington, and G. I. Evan (1992). Cooperative interaction between c-myc and _bcl_-2 proto-oncogenes. Nature359:554–557. Google Scholar
R. Jäger, U. Herzer, J. Schenkel, and H. Weiher (1997). Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates _c-myc_-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene15:1787–1795. Google Scholar
W. J. Muller, C. L. Arteaga, S. K. Muthuswamy, P. M. Siegel, M. A. Webster, R. D. Cardiff, K. S. Meise, F. Li, S.A. Halter, and R. J. Coffey (1996). Synergistic interaction of the neu proto-oncogene product and transforming growth factor α in the mammary epithelium of transgenic mice. Mol. Cell. Biol.16:5726–5736. Google Scholar
D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire (1987). Human breast cancer: Correlation of relapse and survival with the amplification of the HER-2/neu oncogene. Science235:177–182. Google Scholar
M. S. Berger, G. W. Locher, S. Saurer, W. J. Gullick, M. D. Waterfield, B. Groner, and N. E. Hynes (1988). Correlation of c-erbB-2 gene amplification and protein expression in human breast cancer with nodal status and nuclear grading. Cancer Res.48:1238–1243. Google Scholar
N. E. Hynes and D. F. Stern (1994). The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta1198:165–184. Google Scholar
M. A. Olayioye, R. M. Neve, H. A. Lane, and N. E. Hynes (2000). The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J.19:1–9. Google Scholar
R. R. Beerli, W. Wels, and N. E. Hynes (1994). Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem.269:23931–23936. Google Scholar
C. J. Sherr and J. M. Roberts (1999). CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev.13:1501–1512. Google Scholar
J. Vlach, S. Hennecke, K. Alevizopoulos, D. Conti, and B. Amati (1996). Growth arrest by the cyclin-dependent inase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J.15:6595–6604. Google Scholar
R. M. Hudziak, G. D. Lewis, M. Winget, B. M. Fendly, H. M. Shepard, and A. Ullrich (1989). P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol.9:1165–1172. Google Scholar
G. D. Lewis, J. A. Lofgren, A. E. McMurtrey, A. Huijens, B.M. Fendly, K.D. Bauer, and M. X. Sliwkowski (1996). Growth regulation of human breast and ovarian tumor cells by heterulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res.56:1457–1465. Google Scholar
M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol.17:2639–2648. Google Scholar
D. Graus-Porta, R. R. Beerli, J. M. Daly, and N. E. Hynes (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J.16:1647–1655. Google Scholar
J. A. Diehl, M. Cheng, M. F. Roussel, and C. J. Sherr (1998). Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev.12:3499–3511. Google Scholar